237 related articles for article (PubMed ID: 31136303)
1. Rapamycin retards epigenetic ageing of keratinocytes independently of its effects on replicative senescence, proliferation and differentiation.
Horvath S; Lu AT; Cohen H; Raj K
Aging (Albany NY); 2019 May; 11(10):3238-3249. PubMed ID: 31136303
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism.
Wang R; Yu Z; Sunchu B; Shoaf J; Dang I; Zhao S; Caples K; Bradley L; Beaver LM; Ho E; Löhr CV; Perez VI
Aging Cell; 2017 Jun; 16(3):564-574. PubMed ID: 28371119
[TBL] [Abstract][Full Text] [Related]
3. Individual response to mTOR inhibition in delaying replicative senescence of mesenchymal stromal cells.
Antonioli E; Torres N; Ferretti M; Piccinato CA; Sertie AL
PLoS One; 2019; 14(1):e0204784. PubMed ID: 30703123
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic ageing is distinct from senescence-mediated ageing and is not prevented by telomerase expression.
Kabacik S; Horvath S; Cohen H; Raj K
Aging (Albany NY); 2018 Oct; 10(10):2800-2815. PubMed ID: 30332397
[TBL] [Abstract][Full Text] [Related]
5. Targeting mTOR signaling by polyphenols: A new therapeutic target for ageing.
Pazoki-Toroudi H; Amani H; Ajami M; Nabavi SF; Braidy N; Kasi PD; Nabavi SM
Ageing Res Rev; 2016 Nov; 31():55-66. PubMed ID: 27453478
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological inhibition of mTOR attenuates replicative cell senescence and improves cellular function via regulating the STAT3-PIM1 axis in human cardiac progenitor cells.
Park JH; Lee NK; Lim HJ; Ji ST; Kim YJ; Jang WB; Kim DY; Kang S; Yun J; Ha JS; Kim H; Lee D; Baek SH; Kwon SM
Exp Mol Med; 2020 Apr; 52(4):615-628. PubMed ID: 32273566
[TBL] [Abstract][Full Text] [Related]
7. Endothelial replicative senescence delayed by the inhibition of MTORC1 signaling involves MicroRNA-107.
Khor ES; Wong PF
Int J Biochem Cell Biol; 2018 Aug; 101():64-73. PubMed ID: 29857052
[TBL] [Abstract][Full Text] [Related]
8. Coming of age: molecular drivers of aging and therapeutic opportunities.
Newgard CB; Sharpless NE
J Clin Invest; 2013 Mar; 123(3):946-50. PubMed ID: 23454756
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin, proliferation and geroconversion to senescence.
Blagosklonny MV
Cell Cycle; 2018; 17(24):2655-2665. PubMed ID: 30541374
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin enhances long-term hematopoietic reconstitution of ex vivo expanded mouse hematopoietic stem cells by inhibiting senescence.
Luo Y; Li L; Zou P; Wang J; Shao L; Zhou D; Liu L
Transplantation; 2014 Jan; 97(1):20-9. PubMed ID: 24092377
[TBL] [Abstract][Full Text] [Related]
11. Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential.
Demidenko ZN; Blagosklonny MV
Aging (Albany NY); 2009 Dec; 1(12):1008-16. PubMed ID: 20157583
[TBL] [Abstract][Full Text] [Related]
12. Cell senescence, rapamycin and hyperfunction theory of aging.
Blagosklonny MV
Cell Cycle; 2022 Jul; 21(14):1456-1467. PubMed ID: 35358003
[TBL] [Abstract][Full Text] [Related]
13. From rapalogs to anti-aging formula.
Blagosklonny MV
Oncotarget; 2017 May; 8(22):35492-35507. PubMed ID: 28548953
[TBL] [Abstract][Full Text] [Related]
14. Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).
Leontieva OV; Demidenko ZN; Blagosklonny MV
Oncotarget; 2015 Sep; 6(27):23238-48. PubMed ID: 26177051
[TBL] [Abstract][Full Text] [Related]
15. Impact on Autophagy and Ultraviolet B Induced Responses of Treatment with the MTOR Inhibitors Rapamycin, Everolimus, Torin 1, and pp242 in Human Keratinocytes.
Xu S; Li L; Li M; Zhang M; Ju M; Chen X; Gu H
Oxid Med Cell Longev; 2017; 2017():5930639. PubMed ID: 28400912
[TBL] [Abstract][Full Text] [Related]
16. Effects of mammalian target of rapamycin inhibitors on cytokine production and differentiation in keratinocytes.
DeTemple V; Satzger I; Walter A; Schaper K; Gutzmer R
Exp Dermatol; 2016 Oct; 25(10):775-82. PubMed ID: 27194247
[TBL] [Abstract][Full Text] [Related]
17. M(o)TOR of pseudo-hypoxic state in aging: rapamycin to the rescue.
Leontieva OV; Blagosklonny MV
Cell Cycle; 2014; 13(4):509-15. PubMed ID: 24496328
[TBL] [Abstract][Full Text] [Related]
18. Rapalogs in cancer prevention: anti-aging or anticancer?
Blagosklonny MV
Cancer Biol Ther; 2012 Dec; 13(14):1349-54. PubMed ID: 23151465
[TBL] [Abstract][Full Text] [Related]
19. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.
Leontieva OV; Blagosklonny MV
Aging (Albany NY); 2010 Dec; 2(12):924-35. PubMed ID: 21212465
[TBL] [Abstract][Full Text] [Related]
20. Suppression of replicative senescence by rapamycin in rodent embryonic cells.
Pospelova TV; Leontieva OV; Bykova TV; Zubova SG; Pospelov VA; Blagosklonny MV
Cell Cycle; 2012 Jun; 11(12):2402-7. PubMed ID: 22672902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
